Interline Therapeutics Alternatives & Competitors
12 companies similar to Interline Therapeutics — We are leveraging advances in genomics, proteomics and computational chemistry t...
Companies similar to Interline Therapeutics
Wren Therapeutics
Stopping the wave of neurodegeneration at its source
Elgia Therapeutics, Inc.
Pioneering novel molecular approaches for the treatment of metabolic, inflammatory, and fi...
Cairn Biosciences
Navigating exclusive paths to new medicines
Harmonic Discovery
Embedding the complexity of disease into the drug discovery process
Track all Interline Therapeutics competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Halda Therapeutics
Taking Hold, Conquering Cancer. Discovering novel medicines to target cancer and overcome...
Amphista Therapeutics Limited
A new approach to targeted protein degradation to bring life-changing medicines to patient...
ProFound Therapeutics
Pioneering the expanded human proteome to reveal a universe of new medicines.
Nimbus Therapeutics
We develop breakthrough medicines for patients through precision small molecule design.
Ranok Therapeutics
Discovering next-gen therapies through targeted protein degradation for safer and more eff...
Kineta (Reverse Merger With Yumanity Therapeutics)
Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfo...
Genomic Vision
Genomic Vision is a French biotech providing tools and services to visualize and character...
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Interline Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Interline Therapeutics on 9 Jun 2026. The 9 companies listed here were last checked between 11 Sep 2024 and 22 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.